A new real-world study has shown that circulating tumor cell (CTC) analysis can guide personalized treatment and improve outcomes for women with advanced or recurrent ovarian cancer. The findings of the study “Tailoring treatment for advanced and/or recurrent ovarian cancer using the response of circulating tumor cells to therapy: a retrospective analysis” suggest that CTC-guided therapy helps extend time on treatment and may predict longer survival.
The research team relied on data from the Onconomics test from RGCC, which provided detailed data on circulating tumor cell counts, biomarker expression, chemosensitivity, and mRNA profiling. This information enabled physicians to tailor therapies more precisely to each patient’s profile. It delivered essential data that enabled personalized treatment decisions and supported improved outcomes for women with ovarian cancer. The findings reinforce the importance of using this test for treatment decision-making in ovarian tumors.
Unlike traditional biopsies, liquid biopsy testing offers a non-invasive, real-time view of tumor evolution. It can identify biomarkers, resistance pathways, and drug sensitivities, supporting more effective treatment decisions. For patients, this means fewer invasive procedures and a more personalized approach to cancer care.
The results of this study add to a growing body of evidence supporting the integration of CTC testing into routine cancer care. As precision medicine continues to advance, RGCC expects that CTC‑guided approaches will play an increasingly important role in tailoring therapies, reducing unnecessary toxicity, and improving survival outcomes.
RGCC extends its congratulations to Prof. Safra and the entire research team for their groundbreaking work and their trust in RGCC’s expertise. Together, these efforts mark a significant step forward in the fight against ovarian cancer.
The publication can be accessed here.
About RGCC International:
RGCC was launched in 2004 by genetics pioneer Dr. Ioannis Papasotiriou who believes that the key to effectively treating cancer lies in personalized medicine. Today, RGCC is a leading innovator in the field of oncology diagnostics. Using world-leading technology, equipment, and innovative techniques, our team of scientists has developed a range of liquid biopsies that help physicians track cancer progression and tailor treatment plans based on individual patient profiles.
For general inquiries, please contact: [email protected]